Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen
Status:
Terminated
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
Primary objectives of this study is to evaluate the effects of CYP2D6 genotypes on time to
progression after tamoxifen treatment in pre- or postmenopausal women with metastatic breast
cancer. Furthermore, we will evaluate the effects of CYP2D6 genotypes on clinical benefit and
response duration to tamoxifen administration in pre- or postmenopausal women with metastatic
breast cancer and also evaluate the effects of CYP2D6 genotypes on the steady state plasma
concentration of tamoxifen and its metabolites